Genome & Company, Merck and Pfizer have signed a clinical trial collaboration and supply agreement to evaluate GEN-001 therapy in oncology indications as part of Phase I/Ib clinical trial.

Under the agreement, the companies will evaluate the safety, tolerability, biological and clinical activities of GEN-001 therapy in combination with human anti-PD-L1 therapy, avelumab.

The study will be sponsored by Genome & Company, while Merck and Pfizer will supply avelumab for the combination trial that is expected to start this year in the US.

Both Merck and Pfizer can access the data from the clinical trial, which has been designed to be a first-in-human (FIH) study, including dose-escalation and expansion cohorts to evaluate the safety and preliminary efficacy.

Genome & Company CEO Dr Jisoo Pae said: “GEN-001 has been developed as the backbone of Genome & Company’s immuno-oncology pipeline, and we are delighted to collaborate with the global leaders in oncology such as Merck and Pfizer on this Phase I/Ib clinical trial for this combination of GEN-001 and avelumab.

“We are excited to investigate how the preclinical data of this combination will be translated to humans. We look forward to initiating this clinical trial in the coming months.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Avelumab in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

The US Food and Drug Administration (FDA) also granted accelerated approval for avelumab to treat metastatic Merkel cell carcinoma (mMCC) and locally advanced or metastatic urothelial carcinoma (mUC).

GEN-001 has immune-modulating activities and comprises a single strain bacteria isolated from the gut of healthy human volunteers.

Last October, Pfizer reported positive results from the Phase III JADE MONO-1 clinical trial of its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients with moderate to severe atopic dermatitis.